
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is expected to experience strong growth due to its track record of innovation, entry into the MDI segment, and upcoming new products. With a seasoned CEO and a large global customer base, the company has a conservative valuation. However, competition and regulatory risks should be taken into consideration when evaluating the stock.
Bears say
Minimed Group is a scaled medical technology company that offers solutions for the management of diabetes, including Automated Insulin Delivery Systems and Smart Multiple Daily Injection Systems. While adoption of diabetes technology is expected to grow quickly, the company faces competition and pressure to offer economically attractive solutions, limiting pricing power and compressing margins. Additionally, reimbursement and coverage structures vary by country, posing potential risks to the company's future success and revenue. With the recent spin-off from Medtronic and access to a $500 million credit facility, the company has a strong balance sheet, but its future success will depend on the successful adoption of its new products and managing costs effectively.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares